Medtech SA designs, develops and markets a new generation of robotized solutions for medical and surgical treatments.
Medtech's first ROSA robot, ROSA Brain, dedicated to neurosurgery, was designed in 2009. It received CE and FDA approval in 2009 and 2011 respectively, authorizing its marketing for clinical use in Europe and the United States.
The ROSA Brain device has the following technical characteristics:
- robotic arm allowing a great freedom in the choice of the trajectories ;
- haptic capabilities that give the neurosurgeon the ability to guide instruments manually within the limits established during planning;
- Medtech's patented, non-contact, non-invasive patient registration system ;
ROSA Brain assists healthcare professionals with open skull neurological surgery, biopsies, electrode implants for cerebral cortex stimulation procedures, deep brain stimulation, etc.
Pathologies affected by the use of ROSA Brain include epilepsy, Parkinson's disease, generalized dystonia, cavernoma, hydrocephalus. ROSA Brain has been used in over thousands of operations. The robot has been the subject of a large number of scientific publications (see wikipedia).
Medtech also developed ROSA Spine, which received FDA approval in January 2016.
Newfund invested in April 2010.
Medtech was IPOed in Paris (Euronext) in November 2013. The company has been acquired by Zimmer Biomet ($ZBH) in July 2016 for €164m.
Medtech SA is based in Montpellier, Southern France.